检索结果-南通市图书馆

Amplitude analysis of the decays D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)

在线全文

学校读者我要写书评

暂无评论

Chinese physics C 2024年第8期48卷 6-33页

作者： M.Ablikim M.N.Achasov p.Adlarson O.Afedulidis X.C.Ai r.Aliberti A.Amoroso Q.An Y.Bai O.Bakina I.Balossino Y.Ban H.-r.Bao V.Batozskaya K.Begzsuren N.Berger M.Berlowski M.Bertani D.Bettoni F.Bianchi E.Bianco A.Bortone I.Boyko r.A.Briere A.Brueggemann H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.F.Chang W.L.Chang G.r.Che G.Chelkov C.Chen C.H.Chen Chao Chen G.Chen H.S.Chen M.L.Chen S.J.Chen S.L.Chen S.M.Chen T.Chen X.r.Chen X.T.Chen Y.B.Chen Y.Q.Chen Z.J.Chen Z.Y.Chen S.K.Choi X.Chu G.Cibinetto F.Cossio J.J.Cui H.L.Dai J.p.Dai A.Dbeyssi r.E.de Boer D.Dedovich C.Q.Deng Z.Y.Deng A.Denig I.Denysenko M.Destefanis F.De Mori B.Fang S.S.Fang W.X.Fang Y.Fang Y.Q.Fang r.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng J.H.Feng Y.T.Feng K.Fischer M.Fritsch C.D.Fu J.L.Fu Y.W.Fu H.Gao Y.N.Gao Yang Gao S.Garbolino I.Garzia p.T.Ge Z.W.Ge C.Geng E.M.Gersabeck B.Ding X.X.Ding Y.Ding Y.Ding J.Dong L.Y.Dong M.Y.Dong X.Dong M.C.Du S.X.Du Z.H.Duan p.Egorov Y.H.Fan J.Fang JA.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl S.Gramigna M.Greco M.H.Gu Y.T.Gu C.Y.Guan Z.L.Guan A.Q.Guo L.B.Guo M.J.Guo r.p.Guo Y.p.Guo A.Guskov J.Gutierrez K.L.Han T.T.Han X.Q.Hao F.A.Harris K.K.He K.L.He F.H.Heinsius C.H.Heinz Y.K.Heng C.Herold T.Holtmann p.C.Hong G.Y.Hou X.T.Hou Y.r.Hou Z.L.Hou B.Y.Hu H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang K.X.Huang L.Q.Huang X.T.Huang Y.p.Huang T.Hussain F.H\"olzken N.H\"usken N.in der Wiesche M.Irshad J.Jackson S.Janchiv J.H.Jeong Q.Ji Q.p.Ji W.Ji X.B.Ji X.L.Ji Y.Y.Ji X.Q.Jia Z.K.Jia D.Jiang H.B.Jiang p.C.Jiang S.S.Jiang T.J.Jiang X.S.Jiang Y.Jiang J.B.Jiao J.K.Jiao Z.Jiao S.Jin Y.Jin M.Q.Jing X.M.Jing T.Johansson S.Kabana N.Kalantar-Nayestanaki X.L.Kang X.S.Kang M.Kavatsyuk B.C.Ke V.Khachatryan A.Khoukaz r.Kiuchi O.B.Kolcu B.Kopf M.Kuessner X.Kui A.Kupsc W.K\"uhn J.J.Lane p.Larin L.Lavezzi T.T.Lei Z.H.Lei H.Leithoff M.Lellmann T.Lenz C.li C.li C.H.li Cheng li D.M.li F.li G.li H.li H.B.li H.J.li H.N.li Hui li J.r.li J.S.li K.li L.J.li L.K.li Lei li M.H.li p.r.li Q.M.li Q.X.li r.li S.X.li T.li W.D.li W.G.li X.li X.H.li X.L.li X.Y.li Y Institute of High Energy physics Chinese Academy of SciencesBeijing 100049China Beihang university Beijing 100191China Bochum ruhr-university D-44780 BochumGermany Budker Institute of Nuclear physics SB rAS(BINp) Novosibirsk 630090Russia Carnegie Mellon university PittsburghPennsylvania 15213USA Central china Normal university Wuhan 430079China Central South university Changsha 410083China china Center of Advanced Science and Technology Beijing 100190China china university of Geosciences Wuhan 430074China Chung-Ang university Seoul06974Republic of Korea COMSATS university Islamabad Lahore CampusDefence RoadOff Raiwind Road54000 LahorePakistan Fudan university Shanghai 200433China GSI Helmholtzcentre for Heavy Ion research GmbH D-64291 DarmstadtGermany Guangxi Normal university Guilin 541004China Guangxi university Nanning 530004China Hangzhou Normal university Hangzhou 310036China Hebei university Baoding 071002China Helmholtz Institute Mainz Staudinger Weg 18D-55099 MainzGermany Henan Normal university Xinxiang 453007China Henan university Kaifeng 475004China Henan university of Science and Technology Luoyang 471003China Henan university of Technology Zhengzhou 450001China Huangshan College Huangshan 245000China Hunan Normal university Changsha 410081China Hunan university Changsha 410082China Indian Institute of Technology Madras Chennai 600036India Indiana university BloomingtonIndiana 47405USA INFN Laboratori Nazionali di Frascati INFN Laboratori Nazionali di FrascatiI-00044FrascatiItaly INFN Laboratori Nazionali di Frascati INFN Sezione di PerugiaI-06100PerugiaItaly INFN Laboratori Nazionali di Frascati University of PerugiaI-06100PerugiaItaly INFN Sezione di Ferrara INFN Sezione di FerraraI-44122FerraraItaly INFN Sezione di Ferrara University of FerraraI-44122FerraraItaly Inner Mongolia university Hohhot 010021China Institute of Modern physics Lanzhou 730000China Institute of physics and Technology Peace Avenue 54BUlaanbaatar 13330Mongolia Instituto de A

Using e^(+)e^(−)annihilation data corresponding to an integrated luminosity of 2.93 fb^(−1)taken at the center-of-mass energy√s=3.773 GeV with the BESIII detector,a joint amplitude analysis is performed on the decays D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)(non-η).The fit fractions of individual components are obtained,and large interferences among the dominant components of the decays D^(0)→a_(1)(1260)π,D^(0)→π(1300)π,D^(0)→ρ(770)ρ(770),and D^(0)→2(ππ)_(S)are observed in both *** the obtained amplitude model,the Cp-even fractions of D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)(non-η)are determined to be(75.2±1.1_(stat).±1.5_(syst.))%and(68.9±1.5_(stat).±2.4_(syst.))%,*** branching fractions of D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)(non-η)are measured to be(0.688±0.010_(stat.)±0.010_(syst.))%and(0.951±0.025_(stat.)±0.021_(syst.))%,*** amplitude analysis provides an important model for the binning strategy in measuring the strong phase parameters of D^(0)→4πwhen used to determine the CKM angleγ(ϕ_(3))via the B^(−)→DK^(−)decay.

关键词： BESIII D^(0)meson decays amplitude analysis Cp-even fraction

A phase 3,double-blind,randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaı¨ve patients with mCrpC in china,Malaysia,Thailand and russia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Urology 2017年第2期4卷 75-85页

作者： Dingwei ye Yiran Huang Fangjian Zhou Keji Xie Vsevolod Matveev Changling li Boris Alexeev ye tian Mingxing Qiu Hanzhong li Tie Zhou peter De porre Margaret Yu Vahid Naini Hongchuan liang Zhuli Wu Yinghao Sun department of Urology Fudan University Shanghai Cancer CenterShanghaiChina department of Urology Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Laboratory of Oncology in South china Sun Yat-sen University Cancer CenterGuangzhouGuangdongChina Guangzhou First Municipal people’s Hospital GuangzhouGuangdongChina department of Urology Russian Academy of Medical SciencesMoscowRussia department of Urology Cancer Institute(Hospital)Peking Union Medical College and Chinese Academy of Medical SciencesBeijingChina department of Oncology Moscow Oncology Research InstituteMoscowRussia department of Stomatology Beijing Friendship HospitalCapital Medical UniversityBeijingChina department of Urology Sichuan Academy of Medical Science&Sichuan Provincial People’s HospitalChengduSichuanChina department of Oncology Peking Union Medical College HospitalBeijingChina department of Urology Changhai HospitalSecond Military Medical UniversityShanghaiChina department of Oncology Janssen Research&DevelopmentBeerseBelgium department of Medical Oncology Janssen Research&DevelopmentSan DiegoCAUSA department of Urology Janssen Research&DevelopmentBeijingChina

Objective:This double-blind,placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate+prednisone(abiraterone)to prednisone alone in chemotherapy-naı¨ve,asymptomatic or mildly symptomatic metastatic castrationresistant prostate cancer(mCrpC)patients from china,Malaysia,Thailand and ***:Adult chemotherapy-naı¨ve patients with confirmed prostate adenocarcinoma,Eastern Cooperative Oncology Group(ECOG)performance status(pS)grade 0e1,ongoing androgen deprivation(serum testosteroneprostate specific antigen(pSA)or radiographic progression were randomized to receive abiraterone acetate(1000 mg,QD)t prednisone(5 mg,BID)or placebo t prednisone(5 mg,BID),until disease progression,unacceptable toxicity or consent *** endpoint was improvements in time to pSA progression(TTpp).results:Totally,313 patients were randomized(abiraterone:n Z 157;prednisone:n Z 156);and baseline characteristics were *** clinical cut-off(median follow-up time:3.9 months),80% patients received treatment(abiraterone:n Z 138,prednisone:n Z 112).Median time to pSA progression was not reached with abiraterone versus 3.8 months for prednisone,attaining 58%reduction in pSA progression risk(Hr=0.418;prateronetreated patients had higher confirmed pSA response rate(50%vs.21%;relative odds=2.4;pre 5 times more likely to achieve radiographic response than prednisonetreated patients(22.9%vs.4.8%,p=0.0369).Median survival was not *** common(≥10% abiraterone ***-treated)adverse events:bone pain(7%vs.14%),pain in extremity(6%vs.12%),arthralgia(10%vs.8%),back pain(7%vs.11%),and hypertension(15%vs.14%).Conclusion:Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naı¨ve men with mCrpC,consistent with global study,thus supporting use of abiraterone in this patient population.

关键词： Abiraterone Chemotherapy-naı¨ve Metastatic castrationresistant prostate cancer prostate specific antigen prednisone

CEpC Technical Design report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An rui An Daniele paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond p.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH university of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui university HefeiAnhui Applied physics department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu university Institute of ScienceVaranasi Bandirma Onyedi Eylul university Bandirma Beihang university Beijing Beijing Computational Science research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal university Beijing Brown university ProvidenceRI Budker Institute of Nuclear physics Novosibirsk Cadi Ayyad university Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo university Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal university WuhanHubei Central South university ChangshaHunan Centro de Fisica Teorica de particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced Science and Technology Beijing china Institute of Atomic Energy Beijing china Jiliang university HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china university of Geosciences Beijing china university of Geosciences WuhanHubei china university of Mining and Technology XuzhouJiangsu china West Normal university NanchongSichuan Chongqing university Department of PhysicsChongqing Chulalongkorn university Bangkok City university of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell university IthacaNY CppM(AMU/IphU&CNrS/INp) Marseille Dalian Minzu university DalianLiaoning Dalian university of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear problems of Joint Institute for Nuclear research(DLNp JINr) Dubna East china university Of Science And Technol

The Circular Electron positron Collider(CEpC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV Damping ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and Damping ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super proton proton Collider(SppC).The CEpC primarily serves as a Higgs *** its baseline design with synchrotron radiation(Sr)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(Ip),resulting in an integrated luminosity of 13 ab^(-1)for two Ips over a decade,producing 2.6 million Higgs *** the Sr power to 50 MW per beam expands the CEpC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design report(TDr)follows the preliminary Conceptual Design report(pre-CDr,2015)and the Conceptual Design report(CDr,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,r&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Determination of the number ofψ(3686)events taken at BESⅢ

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese physics C 2024年第9期48卷 8-20页

作者： M.Ablikim M.N.Achasov p.Adlarson O.Afedulidis X.C.Ai r.Aliberti A.Amoroso Q.An Y.Bai O.Bakina I.Balossino Y.Ban H.-r.Bao V.Batozskaya K.Begzsuren N.Berger M.Berlowski M.Bertani D.Bettoni F.Bianchi E.Bianco A.Bortone I.Boyko r.A.Briere A.Brueggemann H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.F.Chang G.r.Che G.Chelkov C.Chen C.H.Chen Chao Chen G.Chen H.S.Chen H.Y.Chen M.L.Chen S.J.Chen S.L.Chen S.M.Chen T.Chen X.r.Chen X.T.Chen Y.B.Chen Y.Q.Chen Z.J.Chen Z.Y.Chen S.K.Choi G.Cibinetto F.Cossio J.J.Cui H.L.Dai J.p.Dai A.Dbeyssi r.E.de Boer D.Dedovich C.Q.Deng Z.Y.Deng A.Denig I.Denysenko M.Destefanis F.De Mori B.Ding X.X.Ding Y.Ding Y.Ding J.Dong L.Y.Dong M.Y.Dong X.Dong M.C.Du S.X.Du Y.Y.Duan Z.H.Duan p.Egorov Y.H.Fan J.Fang J.Fang S.S.Fang W.X.Fang Y.Fang Y.Q.Fang r.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng J.H.Feng Y.T.Feng M.Fritsch C.D.Fu J.L.Fu Y.W.Fu H.Gao X.B.Gao Y.N.Gao Yang Gao S.Garbolino I.Garzia L.Ge p.T.Ge Z.W.Ge C.Geng E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl S.Gramigna M.Greco M.H.Gu Y.T.Gu C.Y.Guan Z.L.Guan A.Q.Guo L.B.Guo M.J.Guo r.p.Guo Y.p.Guo A.Guskov J.Gutierrez K.L.Han T.T.Han F.Hanisch X.Q.Hao F.A.Harris K.K.He K.L.He F.H.Heinsius C.H.Heinz Y.K.Heng C.Herold T.Holtmann p.C.Hong G.Y.Hou X.T.Hou Y.r.Hou Z.L.Hou B.Y.Hu H.M.Hu J.F.Hu S.L.Hu T.Hu Y.Hu G.S.Huang K.X.Huang L.Q.Huang X.T.Huang Y.p.Huang T.Hussain F.Hölzken N.Hüsken N.in der Wiesche J.Jackson S.Janchiv J.H.Jeong Q.Ji Q.p.Ji W.Ji X.B.Ji X.L.Ji Y.Y.Ji X.Q.Jia Z.K.Jia D.Jiang H.B.Jiang p.C.Jiang S.S.Jiang T.J.Jiang X.S.Jiang Y.Jiang J.B.Jiao J.K.Jiao Z.Jiao S.Jin Y.Jin M.Q.Jing X.M.Jing T.Johansson S.Kabana N.Kalantar-Nayestanaki X.L.Kang X.S.Kang M.Kavatsyuk B.C.Ke V.Khachatryan A.Khoukaz r.Kiuchi O.B.Kolcu B.Kopf M.Kuessner X.Kui N.Kumar A.Kupsc W.Kühn J.J.Lane p.Larin L.Lavezzi T.T.Lei Z.H.Lei M.Lellmann T.Lenz C.li C.li C.H.li Cheng li D.M.li F.li G.li H.B.li H.J.li H.N.li Hui li J.r.li J.S.li Ke li L.J.li L.K.li Lei li M.H.li p.r.li Q.M.li Q.X.li r.li S.X.li T.li W.D.li W.G.li X.li X.H.li X.L.li X.Z.li Xi Institute of High Energy physics Beijing 100049China Beihang university Beijing 100191China Bochum ruhr-university D-44780BochumGermany Budker Institute of Nuclear physics SB rAS(BINp) Novosibirsk 630090Russia Carnegie Mellon university PittsburghPennsylvania 15213USA Central china Normal university Wuhan 430079China Central South university Changsha 410083China china Center of Advanced Science and Technology Beijing 100190China china university of Geosciences Wuhan 430074China Chung-Ang university Seoul06974Republic of Korea COMSATS university Islamabad Lahore CampusDefence RoadOff Raiwind Road54000LahorePakistan Fudan university Shanghai 200433China GSI Helmholtzcentre for Heavy Ion research GmbH D-64291DarmstadtGermany Guangxi Normal university Guilin 541004China Guangxi university Nanning 530004China Hangzhou Normal university Hangzhou 310036China Hebei university Baoding 071002China Helmholtz Institute Mainz Staudinger Weg 18D-55099MainzGermany Henan Normal university Xinxiang 453007China Henan university Kaifeng 475004China Henan university of Science and Technology Luoyang 471003China Henan university of Technology Zhengzhou 450001China Huangshan College Huangshan 245000China Hunan Normal university Changsha 410081China Hunan university Changsha 410082China Indian Institute of Technology Madras Chennai 600036India Indiana university BloomingtonIndiana 47405USA INFN Laboratori Nazionali di Frascati (A)INFN Laboratori Nazionali di FrascatiI-00044FrascatiItaly(B)INFN Sezione di PerugiaI-06100PerugiaItaly(C)University of PerugiaI-06100PerugiaItaly INFN Sezione di Ferrara (A)INFN Sezione di FerraraI-44122FerraraItaly(B)University of FerraraI-44122FerraraItaly Inner Mongolia university Hohhot 010021China Institute of Modern physics Lanzhou 730000China Institute of physics and Technology Peace Avenue 54BUlaanbaatar 13330Mongolia Instituto de Alta Investigación Universidad de TarapacáCasilla 7DArica 1000000Chile Jilin university Changchun 130012China Joha

The number ofψ(3686)events collected by the BESⅢdetector during the 2021 run period is determined to be(2259.3±11.1)×10~6 by counting inclusiveψ(3686)hadronic *** uncertainty is systematic and the statistical uncertainty is ***,the numbers ofψ(3686)events collected during the 2009 and 2012run periods are updated to be(107.7±0.6)×10~6 and(345.4±2.6)×10~6,*** numbers are consistent with the previous measurements within one standard *** total number ofψ(3686)events in the three data samples is(2712.4±14.3)×10~6.

关键词： ψ(3686) inclusive process Hadronic events BESⅢdetector

Elucidation of Immune regulation Mechanism of renshen Guben Oral liquid by Network pharmacology and Molecular Docking

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Traditional Chinese Medicine 2023年第4期9卷 419-429页

作者： Ying-Ying Tan Ying-Ying liu Jing-Yuan Zhang Jia-lin li pei-Zhi ye Antony Stalin Xiao-tian Fan Zhi-Hong Huang Bing li Chao Wu Shan Lu Zhi-Shan Wu Xiao-Meng Zhang Guo-liang Cheng Jia-rui Wu Yan-Fang Mou department of Clinical Chinese pharmacy School of Chinese Materia MedicaBeijing University of Chinese MedicineBeijingChina Traditional Chinese Medicine department Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina department of Bioinformatics Institute of Fundamental and Frontier SciencesUniversity of Electronic Science and Technology of ChinaChengduChina department of Traditional Chinese Medicine State Key Laboratory of Generic Manufacture Technology of Chinese Traditional MedicineLinyiChina

Objective:To investigate the mechanism of renshen Guben oral liquid(rSGB)enhancing immune *** and Methods:Network pharmacology and molecular docking were used to intuitively demonstrate the mechanism of immune regulation of ***:A total of 112 active compounds of rSGB were found,and 501 targets were ***,2974 immune targets were obtained from Uniprot and NCBI Gene databases,and 111 common targets of rSGB and immunity were *** them,interleukin(IL)6,tumor necrosis factor,AKT1,VEGFA,STAT3,MApK1,SrC,EGFr,IL1B,and pTGS2 might be the key targets for rSGB to improve *** and Kyoto Encyclopedia of Genes and Genomes analysis showed that the immunoregulatory mechanism of rSGB may find a relation with the B cell receptor signaling pathway and T cell receptor signaling ***,this study preliminarily explored the mechanism of rSGB improving menopausal syndrome,polycystic ovary syndrome,and cancer-related fatigue by enhancing ***:rSGB can improve the body's immunity through multicomponent,multitarget,and *** addition,rSGB can also improve the immune capacity of the body to assist in the treatment of diseases,which has great potential as an immunomodulator.

关键词： Immunity molecular docking network pharmacology renshen Guben oral liquid

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia(2021 Edition)

在线全文

学校读者我要写书评

暂无评论

Military Medical research 2022年第5期9卷 515-533页

作者： Xian-Tao Zeng Ying-Hui Jin Tong-Zu liu Fang-Ming Chen De-Gang Ding Meng Fu Xin-Quan Gu Bang-Min Han Xing Huang Zhi Hou Wan-li Hu Xin-li Kang Gong-Hui li Jian-Xing li pei-Jun li Chao-Zhao liang Xiu-Heng liu Zhi-Yu liu Chun-Xiao liu Jiu-Min liu Guang-Heng Luo Yi Luo Wei-Jun Qin Jian-Hong Qiu Jian-Xin Qiu Xue-Jun Shang Ben-Kang Shi Fa Sun Guo-Xiang tian ye tian Feng Wang Feng Wang Yin-Huai Wang Yu-Jie Wang Zhi-ping Wang Zhong Wang Qiang Wei Min-Hui Xiao Wan-Hai Xu Fa-Xian Yi Chao-Yang Zhu Qian-Yuan Zhuang li-Qun Zhou Xiao-Feng Zou Nian-Zeng Xing Da-lin He Xing-Huan Wang 无 department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan430071China Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan430071China department of Urology Tianjin Third Central Hospital Affiliated To Nankai UniversityTianjin300170China department of Urology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China department of Urology Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China department of Urology China-Japan Union Hospital of Jilin UniversityChangchun130033China department of Urology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai200080China department of Urology Qinghai University Affiliated HospitalXi’ning810012China department of Urology People’s Hospital of Hainan ProvinceHainan Affiliated Hospital of Hainan Medical University HaikouHaikou570311China department of Urology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou310016China department of Urology General Hospital of Ningxia Medical UniversityYinchuan750003China department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefei230022China department of Urology Renmin Hospital of Wuhan UniversityWuhan430060China department of Urology The Second Hospital of Dalian Medical UniversityDalian116023LiaoningChina department of Urology Zhujiang Hospital of Southern Medical UniversityGuangzhou510282China department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou510080China department of Urology Surgery Guizhou Province People’s HospitalGuiyang550002China department of Urology Xijing Hospital of Air Force Military Medical UniversityXi’an710032China department of Urology The 980St Hospital of the PLA Joint Logistics Support Force(Bethune International Peace Hospital of PLA)Shijiazhuang050082China department of Urology

Benign prostatic hyperplasia (BpH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUpKp) is one of the foremost surgical procedures for the treatment of BpH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUpKp for BpH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUpKp in the treatment of BpH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUpKp for BpH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUpKp in the treatment of BpH included indications and contraindications for TUpKp, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different

关键词： Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia recommendation Treatment Guideline

Epidemiology of urticaria in china:a population-based study

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2022年第11期135卷 1369-1375页

作者： Jiaqing li Dandan Mao Shuoshuo liu ping liu Jing tian Chenhong Xue Xiaojing liu ruiqun Qi Bingxue Bai Jianjun Nie Siqi ye Yu Wang Yuye li Qing Sun Juan Tao Shuping Guo Hong Fang Jianqin Wang Qiri Mu Quanzhong liu Yan Ding Jianzhong Zhang department of Dermatology Peking University People’s HospitalBeijing 100044China department of Dermatology Beijing Children’s HospitalCapital Medical UniversityBeijing 100045China department of Dermatology Henan Provincial People’s HospitalZhengzhouHenan 450003China Optical Medicine Institute of Tongji university in Shanghai Skin Disease Hospital Shanghai 200071China department of Dermatology The First Hospital of China Medical UniversityShenyangLiaoning 110001China department of Dermatology The Second Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150001China department of Dermatology Chengdu Second People’s HospitalChengduSichuan 610017China department of Dermatology The Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhouGuangdong 510120China department of Dermatology Affiliated Hospital of Guizhou Medical UniversityGuiyangGuizhou 550004China department of Dermatology The First Affiliated Hospital of Kunming Medical UniversityKunmingYunnan 650031China department of Dermatology Qilu Hospital of Shandong UniversityJinanShandong 250012China department of Dermatology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430022China department of Dermatology First Affiliated Hospital of Shanxi Medical UniversityTaiyuanShanxi 030001China department of Dermatology The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiang 310003China department of Dermatology Guangzhou Institute of DermatologyGuangzhouGuangdong 510095China department of Dermatology Inner Mongolia People’s HospitalHohhotInner Mongolia 010017China department of Dermatology Tianjin Medical University General HospitalTianjin 300052China department of Dermatology Hainan Provincial Hospital of Skin DiseaseHaikouHainan 570206China.

Background:Urticaria is a common skin disease characterized by episodes of wheals,and it has a negative effect on patients’quality of ***-scale population-based epidemiological studies of urticaria are scarce in *** aim of this survey was to determine the prevalence,clinical forms,and risk factors of urticaria in the Chinese ***:This survey was conducted in 35 cities from 31 provinces,autonomous regions,and municipalities of *** to three communities in each city were selected in this *** completed questionnaires and received dermatological *** analyzed the prevalence,clinical forms,and risk factors of ***:In total,44,875 questionnaires were distributed and 41,041 valid questionnaires were collected(17,563 male and 23,478 female participants).The lifetime prevalence of urticaria was 7.30%,with 8.26%in female and 6.34%in male individuals(ppoint prevalence of urticaria was 0.75%,with 0.79%in female and 0.71%in male individuals(pr prevalence of urticaria than adolescents and *** in urban areas,exposure to pollutants,an anxious or depressed psychological status,a personal and family history of allergy,thyroid diseases,and Helicobacter pylori infection were associated with a higher prevalence of *** was correlated with a reduced risk of ***:This study demonstrated that the lifetime prevalence of urticaria was 7.30%and the point prevalence was 0.75%in the Chinese population;women had a higher prevalence of urticaria than *** factors were correlated with urticaria.

关键词： Urticaria prevalence risk factor china

Current status of diagnosis and treatment of bladder cancer in china-Analyses of Chinese Bladder Cancer Consortium database

在线全文

学校读者我要写书评

暂无评论

Asian Journal of Urology 2015年第2期2卷 63-69页

作者： Kaiwen li tianxin lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong li Lulin Ma Guoliang Wang Chaozhao liang Haoqiang Shi Ming li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong liu Jinxin Wei Lei Shi Xin Gou Weiyang He liqun Zhou lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun ye tian Lang Feng Tiejun pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei ping Han Changli Wu Dawei tian Zhangqun ye Zheng liu Zhiping Wang Junqiang tian lin Qi Minfeng Chen Wei li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang liu Jin Yang Jianyun Hu Xin Gao Jielin li Changjun Yin pu li Shan Chen Zhen Du Jiongming li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong li Jin Wen Jian Huang department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouChina Chinese Bladder Cancer Consortium department of Urology Renji HospitalShanghai Jiaotong University School of MedicineShanghaiChina department of Urology Fujian Medical University Union HospitalFuzhouChina department of Urology General Hospital of Ningxia Medical UniversityYinchuanChina department of Urology Peking University Third HospitalBeijingChina department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefeiChina department of Urology The Xinjiang Uygur Autonomous Region People’s HospitalUygurChina department of Urology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina department of Urology The First Affiliated Hospital of Guangxi Medical UniversityNanningChina department of Urology Southwest HospitalThird Military Medical UniversityChongqingChina department of Urology Daping HospitalThird Military Medical UniversityChongqingChina department of Urology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina department of Urology The First Affiliated Hospital of Chongqing Medical UniversityChongqingChina department of Urology Peking University First HospitalBeijingChina department of Urology The First Affiliated Hospital of Zhejiang UniversityHangzhouChina department of Urology China Japan Friendship Hospital of Jilin UniversityChangchunChina department of Urology Beijing Friendship HospitalCapital Medical UniversityBeijingChina department of Urology Wuhan General Hospital of Guangzhou MilitaryWuhanChina department of Urology The First Affiliated Hospital of Shanxi UniversityTaiyuanChina department of Urology Qilu Hospital of Shandong UniversityJinanChina department of Urology West China HospitalSichuan UniversityChengduChina department of Urology The Second Affiliated Hospital of Tianjin Medical UniversityTianjinChina department of Urology Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Objective:To investigate current status of diagnosis and treatment of bladder cancer in ***:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were *** of diagnosis,treatment and pathology were ***:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,***-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,*** transurethral resection(TUr)provided detection rate of 16.9%.Most NMIBCs were treated with TUr(89.2%).After initial TUr,2.6%accepted second TUr,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,*** MIBCs were treated with radical cystectomy(rC,59.7%).Laparoscopic rCs were 35.1%,while open rC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,*** most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant ***:Disease characteristics are similar to international reports,while differences of diagnosis and treatment *** study can provide evidences for revisions of the guideline on bladder cancer in china.

关键词： Bladder cancer Diagnosis Treatment

Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Urology 2019年第1期6卷 114-121页

作者： liqun Zhou Kaiwei Yang Xuesong li Yi Ding Dawei Mu Hanzhong li Yong Yan Jinyi li Dongwen Wang Wei li Yulong Cong Jiangping Gao Kewei Ma Yajun Xiao Sheng Zhang Hongyi Jiang Weilie Hu Qiang Wei Xunbo Jin Zhichen Guan Qingyong liu Danfeng Xu Xin Gao Yongguang Jiang Weimin Gan Guang Sun Qing Wang Yanhui liu Jianquan Hou liping Xie Xishuang Song Fengshuo Jin Jiafu Feng Ming Cai Zhaozhao liang Jie Zhang Dingwei ye lin Qi Lulin Ma Jianzhong Shou Yuping Dai Jianyong Shao ye tian Shizhe Hong Tao Xu Chuize Kong Zefeng Kang Yuexin liu Xun Qu Benkang Shi Shaobin Zheng Yi lin Shujie Xia Dong Wei Jianbo Wu Weiling Fu Zhiping Wang Jianbo liang department of Urology Peking University First HospitalBeijingChina Institute of Urology Peking UniversityBeijingChina National Urological Cancer Center BeijingChina Air Force General Hospital PLABeijingChina department of Urology Peking Union Medical College HospitalBeijingChina department of Urology Beijing Chao-Yang HospitalBeijingChina department of Urology Armed-Police General HospitalBeijingChina department of Urology Shanxi Medical University First HospitalTaiyuanChina department of Urology Hebei Medical University Second HospitalShijiazhuangChina department of Urology The General Hospital of the People’s Liberation ArmyBeijingChina department of Urology First Affiliated Hospital of Jilin UniversityChangchunChina department of Urology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina department of pathology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina department of Urology The Second Xiangya Hospital of Central South UniversityChangshaChina department of Urology General Hospital of Guangzhou Military Command of PLAGuangzhouChina department of Urology West China School of MedicineChengduChina department of Urology Shangdong Province-owned HospitalJinanChina department of Urology Peking University Shenzhen HospitalShenzhenChina department of Urology The Central Hospital of Jinan CityJinanChina department of Urology Shanghai Changzheng HospitalShanghaiChina department of Urology The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina department of Urology Beijing Anzhen Hospital of Capital Medical UniversityBeijingChina department of Urology The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina department of Urology The Second Hospital of Tianjin Medical UniversityTianjinChina department of Urology People’s Hospital of Xinjiang Uygur Autonomous RegionWulumuqiChina department of Urology Guangdong General HospitalGuangzhouChina department of Urology The First Affil

Objective:To evaluate the diagnostic value of fluorescence in situ hybridization(FISH)in bladder ***:We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December *** operating characteristic(rOC)curve analysis was performed and the area under curve(AUC)values were calculated for both the FISH and urine cytology ***:A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population.A total of 4807 patients with hematuria were prospectively,randomly enrolled for the simultaneous analysis of urine cytology,FISH testing,and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised ***,the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%,while that of cytology was 33.4%(pr non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7%and 89.6%,respectively(p=0.004).The sensitivity values of FISH for low and high grade bladder cancer were 82.6%and 90.1%,respectively(p=0.002).Conclusion:FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and *** sensitivity using FISH was obtained in high grade and muscle invasive tumors.

关键词： Bladder transitionalcell carcinoma Fluorescence in situ hybridization Detection Grade Stage